Inconsistencies of absolute drug–drug contraindication reports: Analysis of Summaries of Product Characteristics of commonly prescribed drugs
Open Access
- 17 April 2023
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2552-2560
Abstract
Aims: Prescribing information should follow a defined structure to help prescribers easily find required information. Often information appears in different sections of Summaries of Product Characteristics (SmPCs) in an inconsistent way. Still unknown is how this inconsistency affects absolute contraindications and how it can be improved. Thisstudy aimed to evaluate the structure of absolute contraindications in SmPCs based on absolute drug–drug contraindications (DDCI) in the section ‘contraindications’ and references to sections ‘special warnings and precautions for use’ (here as ‘warnings’) and ‘interaction with other medicinal products and other forms of interaction’ (here as ‘interactions’).Methods: SmPCs of 693 commonly prescribed drugs were analysed regarding absolute DDCI in ‘contraindications’ sections. References to sections on ‘warnings’ and ‘interactions’ were evaluated to characterize information provided about DDCI.Results: Of 693 analysed SmPCs, 138 (19.9%) contained ≥1 absolute DDCI. Of 178 SmPCs that referred to sections on ‘warnings’ or ‘interactions’, 131 (73.6%) did not contain further information on absolute DDCI, whereas 47 (26.4%) did. Such additional information was found in sections on ‘interactions’ and ‘warnings’ in 41 (87.2%) and 9 (19.1%) SmPCs, respectively.Conclusions: Information regarding absolute DDCI was found not only in sections on ‘contraindications’ but also in sections on ‘warnings’ and ‘interactions’. Information was not given with consistently straightforward phrasing and structure and so can leave uncertainty for prescribers. To improve drug safety, clear definitions and wording for absolute and relative contraindications should be provided, ideally in tables.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01ZZ1910C, 01ZZ1910O)
This publication has 14 references indexed in Scilit:
- Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic ImpairmentFrontiers in Pharmacology, 2019
- Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence StudyFrontiers in Pharmacology, 2019
- Arzneiverordnungs-Report 20192019
- Assessing the information in the Summaries of Product Characteristics for the use of medicines in pregnancy and lactationBritish Journal of Clinical Pharmacology, 2015
- Inconsistencies and Misleading Information in Officially Approved Prescribing Information From Three Major Drug MarketsClinical Pharmacology & Therapeutics, 2014
- Evaluation of Contraindicated Drug-Drug Interaction Alerts in a Hospital SettingAnnals of Pharmacotherapy, 2011
- Improving the usability of patient information leafletsPatient Education and Counseling, 2010
- Differences in product information of biopharmaceuticals in the EU and the USA: implications for product developmentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2005
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Hospital Admissions Resulting from Preventable Adverse Drug ReactionsAnnals of Pharmacotherapy, 2002